Included in the formulation
АТХ:C.10.A.B.08 Ciprofibrate
Pharmacodynamics:Pharmacological action - lipid-lowering.
It blocks HMG-CoA reductase, disrupts the formation of mevalonic acid (an intermediate product of steroids). Inhibits the synthesis of cholesterol in the liver. Reduces total cholesterol and triglycerides in blood plasma; increases the level of HDL, reduces - VLDL and LDL, promotes lysis of fibrin and regression of tendon xanthoma (with prolonged use).
Pharmacokinetics:Absolutely absorbed in the digestive tract. Maximum concentration is achieved after 2 hours. It strongly binds to plasma proteins. In the liver and kidneys forms conjugates with glucuronic acid. Half-life is 80 hours. It is excreted unchanged in urine or in the form of glucuronides. Do not cumulate.
Indications:Endogenous hypercholesterolemia (isolated, associated) and hypertriglyceridemia, not corrected by diet and exercise; presence of risk factors for hypercholesterolemia.
IV.E70-E90.E78.1 Pure hyperglyceridemia
IV.E70-E90.E78.0 Pure hypercholesterolemia
IV.E70-E90.E78.2 Mixed hyperlipidemia
Contraindications:Hypersensitivity, renal, hepatic insufficiency, pregnancy, breast-feeding, children's age.
Pregnancy and lactation:Recommendations for FDA - category X. There is no information. Do not apply!
There is no information on the penetration into breast milk. Do not apply!
Dosing and Administration:For oral intake of daily dose is 100-200 mg, the frequency of reception - 1 time per day. In hypoalbuminemia, a dose reduction is necessary.
Side effects:From the side nervous system: headache, weakness, asthenia.
From the side digestive system: nausea, transient increase in hepatic transaminase activity in blood plasma, exacerbation of cholelithiasis.
From the side musculoskeletal system: myasthenia gravis, myositis, myalgia.
Dermatological reactions: skin rash.
From the side laboratory indicators: rarely - an increase in the level of creatine phosphokinase and LDH.
Overdose:Not described.
Treatment symptomatic: stimulation of vomiting, gastric lavage, intake of activated charcoal; control of liver function and activity of creatine phosphokinase.
There is no specific antidote; Hemodialysis is ineffective.
Interaction:Incompatible with hepatotoxic agents (male peraxillite, MAO inhibitors), enhances the effect of indirect anticoagulants (antivitamins K).
Derivatives of nicotinic acid and other hypocholesterolemic drugs increase the effectiveness of the application.
Special instructions:If the 3-6-month period is ineffective, combined therapy is necessary. At the time of treatment, careful monitoring of the level and activity of liver transaminases is necessary: if the activity of serum ALT exceeds 100 units, ciprofibrate cancel. At simultaneous appointment with indirect anticoagulants (under the control of prothrombin) it is recommended to reduce the dose of the latter by 30%.
Hypoalbuminemia causes the need to reduce doses (selected individually).